疑似严重急性呼吸综合征（SARS）患者中针对SARS相关冠状病毒核衣壳蛋白的抗体谱
Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients.
作者信息
Liu Xuan, Shi Yulin, Li Ping, Li Linhai, Yi Yanping, Ma Qingjun, Cao Cheng
机构信息
Beijing Institute of Biotechnology, Beijing 100850, Peoples Republic of China.
出版信息
Clin Diagn Lab Immunol. 2004 Jan;11(1):227-8. doi: 10.1128/cdli.11.1.227-228.2004.
Abstract
Profiles of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in 445 probable SARS patients and 3,749 healthy people or non-SARS patients were analyzed by antigen-capturing enzyme-linked immunosorbent assay. Antinucleocapsid antibodies were elucidated in 17.5% of the probable SARS patients 1 to 7 days after the onset of symptoms and in 80% of the patients 8 to 14 days after the onset. About 90% of the probable SARS patients were positive 15 or more days after illness. Antibody titers increased up to 70 days, and high antibody titers were maintained at least for another 3 months. Of the healthy people and non-SARS patients, only seven (0.187%) were weakly positive.
摘要
采用抗原捕获酶联免疫吸附试验分析了445例疑似严重急性呼吸综合征（SARS）患者以及3749例健康人或非SARS患者针对SARS相关冠状病毒核衣壳蛋白的抗体谱。17.5%的疑似SARS患者在症状出现后1至7天可检测到抗核衣壳抗体，80%的患者在症状出现后8至14天可检测到。约90%的疑似SARS患者在发病15天及以上呈阳性。抗体滴度在70天内升高，高抗体滴度至少维持3个月。在健康人和非SARS患者中，只有7人（0.187%）呈弱阳性。
相似文献
1
Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients.疑似严重急性呼吸综合征（SARS）患者中针对SARS相关冠状病毒核衣壳蛋白的抗体谱
Clin Diagn Lab Immunol. 2004 Jan;11(1):227-8. doi: 10.1128/cdli.11.1.227-228.2004.
2
Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus.严重急性呼吸综合征（SARS）冠状病毒所致肺炎患者针对SARS冠状病毒核衣壳蛋白的免疫球蛋白G（IgG）、IgM和IgA抗体的纵向变化情况
Clin Diagn Lab Immunol. 2004 Jul;11(4):665-8. doi: 10.1128/CDLI.11.4.665-668.2004.
3
Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay.通过抗原捕获酶联免疫吸附测定法检测严重急性呼吸综合征（SARS）冠状病毒核衣壳抗体来诊断严重急性呼吸综合征（SARS）
J Clin Microbiol. 2003 Dec;41(12):5781-2. doi: 10.1128/JCM.41.12.5781-5782.2003.
4
Detection of specific antibodies to severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia.检测针对严重急性呼吸综合征（SARS）冠状病毒核衣壳蛋白的特异性抗体用于SARS冠状病毒肺炎的血清学诊断。
J Clin Microbiol. 2004 May;42(5):2306-9. doi: 10.1128/JCM.42.5.2306-2309.2004.
5
Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA.通过免疫印迹法或酶联免疫吸附测定法评估针对严重急性呼吸综合征冠状病毒核衣壳蛋白或刺突蛋白的抗体反应。
J Med Virol. 2004 Jul;73(3):338-46. doi: 10.1002/jmv.20096.
6
Recombinant protein-based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins.基于重组蛋白的检测严重急性呼吸综合征冠状病毒刺突蛋白和核衣壳蛋白抗体的检测方法。
Clin Vaccine Immunol. 2007 Mar;14(3):331-3. doi: 10.1128/CVI.00351-06. Epub 2007 Jan 17.
7
Double-antigen sandwich ELISA for detection of antibodies to SARS-associated coronavirus in human serum.用于检测人血清中严重急性呼吸综合征相关冠状病毒抗体的双抗原夹心酶联免疫吸附测定法
Eur J Clin Microbiol Infect Dis. 2005 Aug;24(8):549-53. doi: 10.1007/s10096-005-1378-7.
8
False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E rectified by Western blotting with recombinant SARS-CoV spike polypeptide.在重组严重急性呼吸综合征相关冠状病毒（SARS-CoV）核衣壳酶联免疫吸附测定中，因HCoV-OC43和HCoV-229E导致的假阳性结果，通过用重组SARS-CoV刺突多肽进行蛋白质免疫印迹法得以纠正。
J Clin Microbiol. 2004 Dec;42(12):5885-8. doi: 10.1128/JCM.42.12.5885-5888.2004.
9
[Antibody response of patients with severe acute respiratory syndrome (SARS) to nucleocapsid antigen of SARS-associated coronavirus].严重急性呼吸综合征（SARS）患者对严重急性呼吸综合征相关冠状病毒核衣壳抗原的抗体反应
Di Yi Jun Yi Da Xue Xue Bao. 2003 Jul;23(7):637-9.
10
Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia.严重急性呼吸综合征（SARS）冠状病毒刺突多肽酶联免疫吸附测定（ELISA）和SARS冠状病毒核衣壳蛋白ELISA在SARS冠状病毒肺炎血清学诊断中的差异敏感性。
J Clin Microbiol. 2005 Jul;43(7):3054-8. doi: 10.1128/JCM.43.7.3054-3058.2005.
引用本文的文献
1
Mixed lipopeptide-based mucosal vaccine elicits a long-term bone marrow memory response that is potentially cross-reactive against a broad-spectrum of coronaviruses in mice.基于混合脂肽的黏膜疫苗在小鼠中引发长期骨髓记忆反应，该反应可能对多种冠状病毒具有交叉反应性。
Front Immunol. 2025 Jul 28;16:1619882. doi: 10.3389/fimmu.2025.1619882. eCollection 2025.
2
Mixed lipopeptide-based mucosal vaccine candidate induces cross-variant immunity and protects against SARS-CoV-2 infection in hamsters.基于混合脂肽的黏膜疫苗候选物可诱导交叉变异免疫并保护仓鼠免受SARS-CoV-2感染。
Immunohorizons. 2025 Jan 24;9(2). doi: 10.1093/immhor/vlae011.
3
Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens.暴露于 SARS-CoV-2 或接种过疫苗的个体中的抗体反应针对多种 CoV-2 抗原的保守表位。
Int J Mol Sci. 2024 Sep 11;25(18):9814. doi: 10.3390/ijms25189814.
4
Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune responses in mice.黏膜免疫接种源自 SARS-CoV-2 抗原保守区域的脂肽可在小鼠中诱导强烈的细胞和交叉变体体液免疫应答。
Front Immunol. 2023 Jun 2;14:1178523. doi: 10.3389/fimmu.2023.1178523. eCollection 2023.
5
A comparative study of antibody response, virus neutralization efficiency & metabolites in SARS-CoV-2-infected adults & children.一项关于 SARS-CoV-2 感染的成年人和儿童的抗体反应、病毒中和效率和代谢物的比较研究。
Indian J Med Res. 2022 Oct-Nov;156(4&5):659-668. doi: 10.4103/ijmr.ijmr_3475_21.
6
Construction and Immunogenicity of a Recombinant Pseudorabies Virus Expressing SARS-CoV-2-S and SARS-CoV-2-N.表达严重急性呼吸综合征冠状病毒2刺突蛋白（SARS-CoV-2-S）和核衣壳蛋白（SARS-CoV-2-N）的重组伪狂犬病病毒的构建及免疫原性
Front Vet Sci. 2022 Aug 2;9:920087. doi: 10.3389/fvets.2022.920087. eCollection 2022.
7
Harnessing immunological targets for COVID-19 immunotherapy.利用免疫靶点进行新冠病毒免疫治疗。
Future Virol. 2021 Jul. doi: 10.2217/fvl-2021-0048. Epub 2021 Aug 9.
8
Common low complexity regions for SARS-CoV-2 and human proteomes as potential multidirectional risk factor in vaccine development.SARS-CoV-2 和人类蛋白质组常见的低复杂度区域可能成为疫苗开发的多向风险因素。
BMC Bioinformatics. 2021 Apr 8;22(1):182. doi: 10.1186/s12859-021-04017-7.
9
Serological assays and host antibody detection in coronavirus-related disease diagnosis.冠状病毒相关疾病诊断中的血清学检测和宿主抗体检测。
Arch Virol. 2021 Mar;166(3):715-731. doi: 10.1007/s00705-020-04874-2. Epub 2021 Jan 25.
10
Benefits and limitations of serological assays in COVID-19 infection.新冠病毒感染中血清学检测的益处与局限性
Indian J Tuberc. 2020 Dec;67(4S):S163-S166. doi: 10.1016/j.ijtb.2020.07.034. Epub 2020 Aug 6.
本文引用的文献
1
Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay.通过抗原捕获酶联免疫吸附测定法检测严重急性呼吸综合征（SARS）冠状病毒核衣壳抗体来诊断严重急性呼吸综合征（SARS）
J Clin Microbiol. 2003 Dec;41(12):5781-2. doi: 10.1128/JCM.41.12.5781-5782.2003.
2
Profile of specific antibodies to the SARS-associated coronavirus.严重急性呼吸综合征相关冠状病毒特异性抗体概况
N Engl J Med. 2003 Jul 31;349(5):508-9. doi: 10.1056/NEJM200307313490520.
3
Personal view of SARS: confusing definition, confusing diagnoses.对非典的个人看法：定义混乱，诊断也混乱。
Lancet. 2003 Jun 7;361(9373):1984-5. doi: 10.1016/s0140-6736(03)13556-8.
4
A novel coronavirus associated with severe acute respiratory syndrome.一种与严重急性呼吸综合征相关的新型冠状病毒。
N Engl J Med. 2003 May 15;348(20):1953-66. doi: 10.1056/NEJMoa030781. Epub 2003 Apr 10.
5
Identification of a novel coronavirus in patients with severe acute respiratory syndrome.在严重急性呼吸综合征患者中鉴定出一种新型冠状病毒。
N Engl J Med. 2003 May 15;348(20):1967-76. doi: 10.1056/NEJMoa030747. Epub 2003 Apr 10.
6
Identification of severe acute respiratory syndrome in Canada.加拿大严重急性呼吸综合征的识别。
N Engl J Med. 2003 May 15;348(20):1995-2005. doi: 10.1056/NEJMoa030634. Epub 2003 Mar 31.
Zotero 插件